GlassScriptPhysician profile
Michel Jose Charles
NPI 1598711459
$3,814.93
in general payments reported to CMS, 2019-2025
20 companies · $952 in 2025
The $952 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,024 · 2020: $255 · 2021: $632 · 2022: $241 · 2023: $67.03 · 2024: $644 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,644 · Debt Forgiveness: $18.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.26 |
| Debt Forgiveness | $18.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $778.25 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $529.39 | 2019-2024 | Xifaxan |
| Abbvie INC. | $516.42 | 2019-2025 | Linzess |
| Redhill Biopharma INC. | $307.85 | 2020-2022 | |
| Gilead Sciences, INC. | $303.10 | 2019-2025 | Livdelzi |
| Braintree Laboratories, INC. | $272.97 | 2019-2024 | Sutab |
| Ardelyx, INC. | $243.10 | 2024-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $173.03 | 2019-2022 | |
| Cumberland Pharmaceuticals, INC. | $170.29 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $144.08 | 2025 | Eohilia |
| Regeneron Healthcare Solutions, INC. | $105.72 | 2023-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $51.62 | 2021 | |
| Shire North American Group INC | $46.26 | 2019 | |
| Opko Pharmaceuticals, LLC | $42.40 | 2024 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $28.51 | 2024 | Farxiga |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $23.50 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $23.44 | 2019 | |
| Merck Sharp & Dohme LLC | $18.74 | 2019 | |
| Baxter Healthcare | $18.30 | 2025 | |
| Allergan, INC. | $17.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michel Jose Charles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.